Segment, Geographical and Other Revenue Information (Tables)

6 Months Ended

Jun. 30, 2022

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


	Three Months Ended June 30, 2022						Three Months Ended June 30, 2021
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	34,645	$	—	$	34,645	$	14,717	$	—	$	14,717
Research and development revenue	1,885		1,876		3,761		6,868		3,868		10,736
Total revenues	36,530		1,876		38,406		21,585		3,868		25,453
Costs and operating expenses:
Cost of product revenue	11,270		—		11,270		4,318		—		4,318
Research and development(1)	6,929		11,078		18,007		5,057		7,194		12,251
Selling, general and administrative(1)	3,876		680		4,556		3,170		620		3,790
Total segment costs and operating expenses	22,075		11,758		33,833		12,545		7,814		20,359
Income (loss) from operations	$	14,455	$	(9,882)	4,573		$	9,040	$	(3,946)	5,094
Corporate costs (2)					(5,789)						(8,610)
Unallocated depreciation and amortization					(1,316)						(741)
Loss before income taxes					$	(2,532)					$	(4,257)


	Six Months Ended June 30, 2022						Six Months Ended June 30, 2021
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	65,335	$	—	$	65,335	$	24,943	$	—	$	24,943
Research and development revenue	4,294		4,117		8,411		10,872		7,670		18,542
Total revenues	69,629		4,117		73,746		35,815		7,670		43,485
Costs and operating expenses:
Cost of product revenue	19,791		—		19,791		8,536		—		8,536
Research and development(1)	13,051		23,424		36,475		11,502		11,799		23,301
Selling, general and administrative(1)	7,416		1,400		8,816		5,988		1,221		7,209
Total segment costs and operating expenses	40,258		24,824		65,082		26,026		13,020		39,046
Income (loss) from operations	$	29,371	$	(20,707)	8,664		$	9,789	$	(5,350)	4,439
Corporate costs (2)					(16,994)						(16,335)
Unallocated depreciation and amortization					(2,549)						(1,426)
Loss before income taxes					$	(10,879)					$	(13,322)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other income (expense), net.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Three Months Ended June 30,
	2022								2021
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	1,283	$	358	$	1,590	$	3,231	$	1,115	$	257	$	1,472	$	2,844


	Six Months Ended June 30,
	2022								2021
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	2,770	$	768	$	3,531	$	7,069	$	2,109	$	495	$	2,927	$	5,531

Schedule of Customers that Contributed 10% or More of Total Accounts Receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues for the
	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Customer A	62	%	15	%	62	%	10	%
Customer B	*		12	%	*		13	%
Customer C	*		12	%	*		*
Customer D	*		*		*		17	%
Customer E	*		*		*		10	%
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:


	Percentage of Accounts Receivables as of
	June 30, 2022		December 31, 2021
Customer A	67	%	62	%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenues
Americas	$	3,614	$	5,844	$	7,347	$	10,773
EMEA	4,690		6,169		8,817		12,450
APAC	30,102		13,440		57,582		20,262
Total revenues	$	38,406	$	25,453	$	73,746	$	43,485

Schedule of Long-Lived Assets by Geographical Area

Identifiable long-lived assets by location was as follows (in thousands):


	June 30, 2022		December 31, 2021
United States	$	65,400	$	65,457

Schedule of Intangible Assets and Goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):


	As of June 30, 2022 and December 31, 2021
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241